BTIG Upgrades CareDx to Buy, Announces $40 Price Target
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Sung Ji Nam has upgraded CareDx (NASDAQ:CDNA) from Neutral to Buy, setting a price target of $40.
August 19, 2024 | 1:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BTIG analyst Sung Ji Nam upgraded CareDx from Neutral to Buy, with a new price target of $40, indicating a positive outlook for the stock.
The upgrade from Neutral to Buy by a reputable analyst and the announcement of a $40 price target suggest increased investor confidence and potential for stock price appreciation. Such analyst actions typically lead to positive short-term movements in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100